[NGS-based multi-gene panel testing in hematological malignancies: therapeutic significance]

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Next-generation sequencing (NGS)-based multigene panel testing assesses hundreds of cancer-associated genes.
• While approved for solid tumors, NGS panel tests are not yet available for hematologic malignancies.
• Current applications of NGS panel tests focus on identifying targeted therapies for solid tumors.

Purpose of the Study:

• To review the advantages of NGS-based multigene panel tests for hematologic malignancies.
• To compare NGS panel tests with conventional diagnostic methods for blood cancers.
• To highlight the role of genomic profiling in guiding therapeutic strategies for hematologic malignancies.

Main Methods:

• Literature review of studies on NGS panel testing in oncology.
• Analysis of current diagnostic and prognostic applications of genomic profiling in hematologic malignancies.
• Comparison of NGS-based approaches with traditional methods for hematologic cancer management.

Main Results:

• NGS panel testing offers comprehensive mutational profiling for a wide range of cancer genes.
• Genomic profiling in hematologic malignancies provides critical diagnostic and prognostic information.
• NGS panel tests have the potential to significantly improve therapeutic strategy selection for blood cancers.

Conclusions:

• NGS-based multigene panel testing holds promise for advancing the diagnosis and treatment of hematologic malignancies.
• Genomic insights from NGS can guide personalized therapeutic decisions, improving patient outcomes.
• Further development and validation are needed for routine clinical implementation in hematologic cancers.